Acta Pharmaceuticals
A $100,000 equity investment listed on CerebrumDAO's dashboard. Acta Pharmaceuticals is a clinical-stage biopharmaceutical company running a Phase 1 trial of an investigational oral compound, GSM-779690T, for Alzheimer's disease. Unlike CerebrumDAO's tokenized IP-NFT deals, later-stage equity investments made without an IP-NFT are not given individual project pages, which is why this one has no dedicated page on cerebrumdao.com.
Documentation note
This project has no dedicated public project page on cerebrumdao.com. Per CerebrumDAO, later-stage equity investments made without an accompanying IP-NFT are not given individual project pages the way tokenized IP-NFT deals are. No governance proposal for this investment was found among CDP-1 through CDP-20. Acta does appear to have a live company domain, actapharmaceuticals.com (confirmed reachable, HTTP 200, and matching the contact email domain on its ClinicalTrials.gov registration) — but it is password-protected with no publicly viewable content. Company-level facts below (founding year, HQ, total funding) come from a third-party aggregator (CB Insights) with an "unclaimed" profile status, not from Acta directly, and are flagged accordingly rather than stated as confirmed. Founded 2022; headquartered at 292 Newbury Street, Boston, MA (per CB Insights, unclaimed profile — not independently confirmed by Acta). Total funding raised reported as $13.4M (per CB Insights, unclaimed profile — not confirmed as an official Acta or CerebrumDAO disclosure, and this figure does not appear anywhere in Acta's own trial registrations or in the allsci.com report).
The science
Problem
Alzheimer's disease — confirmed as the trial's registered condition on ClinicalTrials.gov (NCT07690228, filed by Acta) and matched by Acta's own LinkedIn company description ("Developing novel treatments for Alzheimer's disease and brain health").
Approach
GSM-779690T, an investigational oral compound now in a Phase 1, randomized, double-blind, placebo-controlled study (ClinicalTrials.gov NCT07690228; not yet recruiting as of the registry's last verified update, 2026-07, with an estimated start date of 2026-08-15), measuring safety, tolerability, pharmacokinetics, and pharmacodynamic changes in Aβ peptide isoforms in 72 healthy adult volunteers at Nucleus Network (Melbourne, Australia). A third-party news report (allsci.com) frames the compound as "likely" a gamma-secretase modulator (GSM), based on inference from those biomarker endpoints, and states directly that "Acta has not publicly disclosed the molecular target or intended indication for GSM-779690T" in that specific sense — treat the GSM mechanism label as third-party inference, not a confirmed company statement. (Note: an earlier, since-withdrawn registration for this program, NCT07155980, did include "gamma-secretase modulator" among its own Acta-authored keywords, which is a partial primary-source counterpoint to that "not disclosed" framing.)
Why CerebrumDAO supported it
Not publicly documented
Organizations
- Nucleus Network Pty Ltd (Melbourne, Australia) — Phase 1 trial site
Sources
- CerebrumDAO dashboard (source for the $100,000 CerebrumDAO investment figure)
- ClinicalTrials.gov NCT07690228 (current active Phase 1 registration)
- ClinicalTrials.gov NCT07155980 (earlier, withdrawn registration)
- AllSci news report on the Phase 1 trial (secondary source — GSM framing is this article's own inference, not quoted as an Acta statement)
- CB Insights company profile (unclaimed — source for founding year, HQ, and total funding only)
- Acta Pharmaceuticals on LinkedIn
Last reviewed: 2026-07-22